The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Generally good results BUT I suspect this section will cause concerns:
Despite the excellent commercial progress being made, the Group's short term
cashflow is currently dependent on the receipt of R&D tax credits (some of
which was expected in December) and material customer payments, one of which
is overdue and others are expected in March and April. This has led the Board
to seek additional funding should these payments not materialise as expected
and contracted. This includes the negotiation of invoice financing facilities
and discussions with a lender for potential bridge funding of up to £1.0
million, the terms of which are expected to be agreed shortly. The Board
remains confident on receipt of adequate funds such that these financial
statements have been prepared on the basis that the Group remains a going
concern, however, there is uncertainty relating to the timely receipt of
customer payments and tax credits in the short term.
IMHO Samsung would not have settled if they were going to pay the reported potential cost of $400m. More likely is a settlement in the $100 - $200m range BUT, there will also be an ongoing licencing agreement as part of the settlement with future payments.
Other companies use quantum dot technology to produce TV's (Vizio, LG, Hisense, and TCL) and they may also have to reach settlements, and pay ongoing licence fees if they use any of Nanoco's IP.
So the daily flows (volume) from Saltfleetby (in MCM / day) since the start are
0.0342
0.0680
0.0324
0.1026
0.0342
0.0680
So very variable and peaking at c0.1 mcm/day
On the Nominations dashboard there are NO entries for Saltfeetby which suggests Angus are not confident yet to commit to a specific volume.
All of this suggests to me there are issues with controlling the equipment and gas flows.
Am I wrong?
I am a holder here.
this scenario was discussed in the latest Justin Waite audiocast - CEO says it could happen, and they'd have to consider offer as that's what the Company rules say, but they also have to consider what is best for shareholders and if refusing bid is best option for shareholders in the long term they would.......
Arcontech unloved and materially under-rated
Flat revenue of £3m and pre-tax profit of £1.02m in 12 months to 30 June 2021.
Net cash up 8 per cent to £5.4m (40.6p a share).
Dividend raised 10 per cent to 2.75p a share.
High level of pent up demand with qualified list of prospective new customers across six countries.
Aim-traded financial software provider Arcontech (ARC:135p) delivered a resilient performance in its latest financial year despite the Covid-19 pandemic restricting customer contact due to remote working practices.
The company makes its money by providing software products and bespoke solutions for the collection, processing, distribution and presentation of time-sensitive financial markets data. Sales cycles are long and complex, which discourages clients from switching to another provider, so face-to-face meetings with key decision makers are key when pitching for a new contract. For instance, Arcontech needs to demonstrate: the potential cost savings of its solutions; how it can replicate the functionality of the clients’ existing products; and how it can deliver new benefits to minimise disruption. New contract awards are small initially and then scale up, so generating organic growth in future years.
Arcontech did manage to win new contracts in the 12-month trading period, one with a Tier One bank client, to add to its roll call of blue-chip clients which includes Barclays, JPMorgan, Morgan Stanley, and Bank of England. The small sales team has also been successful in strengthening the qualified pipeline of potential prospects, but Covid-19 restrictions have made converting the robust pipeline of opportunities difficult in the near-term, hence why the directors expect current year profits to be flat (or lower) as any pick up in revenue will not be fully reflected until the 2022/23 financial year.
The market reaction has been savage with Arcontech’s share price plunging below the 160p level at which I suggested buying at six months ago (‘Tap into a prodigious cash generator’, 28 February 2021). It’s a ridiculous overreaction. At the current price, the company has an enterprise valuation of £12.6m, or 12 times net profit, a low-ball valuation for a high margin (operating margin of 36 per cent), cash generative (free cash flow of £0.8m forecast in 2021/22) business that has strong defensive characteristics (recurring licence fees account for 93 per cent of annual revenue). Arcontech is also highly operationally geared given its relatively fixed cost base. Indeed, the incremental operating margin on new sales is around 60 per cent, so any contract wins have an accentuated impact on profits. Moreover, at the current valuation Arcontech is an obvious takeover target in a consolidating industry with peers trading on PE ratios of between 32 and 43 times. Recovery buy.